Patents by Inventor E. Magnus Ohman

E. Magnus Ohman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6662114
    Abstract: A method for predicting the clinical outcome for a patient after the patient has received therapy for an acute coronary syndrome such as myocardial infarction comprises: (a) optionally, but preferably, detecting a first variable comprising a serum creatine kinase-MB release curve area in the patient after initiation of said therapy; (b) detecting a second variable comprising a serum creatine kinase-MB release curve maxima in the patient after initiation of said therapy; then (c) optionally, but preferably, detecting a third variable comprising the slope of the descending portion of the serum creatine kinase-MB release curve after initiation of said therapy (wherein a steep slope for said descending portion is a more favorable indicator of clinical outcome than a shallow slope); and (d) generating a prediction of clinical outcome for said patient from the variables collected above.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: December 9, 2003
    Assignees: Duke University, University of Maryland
    Inventors: Robert H. Christenson, Show-Hong Duh, Robin T. Vollmer, E. Magnus Ohman, Trevor D. Thompson, L. Kristin Newby, Robert M. Califf
  • Patent number: 6033364
    Abstract: The present invention is a method of diagnosing the presence of a persistent occlusion in a myocardial infarct patient undergoing thrombolytic therapy. The method comprises detecting a series of five variables from the patient and then generating the probability of the presence of a persistent occlusion from those variables. The first variable comprises a serum creatine kinase MB (CK-MB) level from a patient at the onset of thrombolytic therapy. The second variable comprises a second CK-MB level in the patient at a predetermined time after the onset of thrombolytic therapy. The third variable comprises the presence or absence of chest pain a predetermined time after the onset of thrombolytic therapy. The fourth variable comprises the serum myoglobin level in the patient at a predetermined time after the onset of thrombolytic therapy.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: March 7, 2000
    Assignee: Duke University
    Inventors: E. Magnus Ohman, Robert H. Christenson, Robert M. Califf, Mary Ann O'Hanesian, Kristina N. Sigmon